Date: 2013-02-14
Type of information: Development agreement
Compound: biosimilar products, insulin analog products
Company: Mylan (USA - PA) Biocon (India)
Therapeutic area: Metabolic diseases
Type agreement: development - commercialisation
Action mechanism: biosimilar/insulin analog
Disease: type 1 diabetes, type 2 diabetes
Details:
- • On June 29, 2009, Mylan announced that it has executed a definitive agreement with Biocon for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. Through this partnership, Mylan and Biocon bring together highly complementary capabilities that will significantly advance their efforts to secure a leading position in the emerging generic biologics industry. As part of this collaboration, Mylan and Biocon will share development, capital and certain other costs to bring products to market. Mylan will have exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand and in the European Union and European Free Trade Association countries through a profit sharing arrangement with Biocon. Mylan will have co-exclusive commercialization rights with Biocon in all other markets around the world. All other financial terms and product details remain confidential.
Financial terms:
Latest news:
- • On February 14, 2013, Biocon announced that it has entered into a definitive agreement with Mylan for an exclusive strategic collaboration for the global development and commercialization of generic versions of its three insulin analog products. Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon’s Glargine (the generic version of Sanofi’s Lantus®), Lispro (the generic version of Eli Lilly's Humalog®) and Aspart (the generic version of Novo Nordisk’s NovoLog®). Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Mylan will have exclusive commercialization rights in the U.S., Canada, Australia, New Zealand, the European Union and the European Free Trade Association countries through a profit share arrangement with Biocon. Mylan will have co-exclusive commercialization rights with Biocon in certain other markets around the world.
Is general: Yes
